黑灵芝多糖对Ⅱ型糖尿病大鼠血糖、血脂及肠系膜上动脉病变改善作用

Protective Effect of Polysaccharide from Ganoderma atrum on Fasting Blood Glucose, Serum Lipids and Arteriosclerotic Narrowing of Superior Mesenteric Arteries in Type Ⅱ Diabetic Rats

目的:研究黑灵芝多糖对糖尿病大鼠血糖、血脂及肠系膜上动脉病变改善作用。方法:高脂高糖结合小剂量链脲佐菌素(STZ)诱导Ⅱ型糖尿病模型,分别灌服黑灵芝多糖(100mg/(kg·d),体质量计)、环孢素A(CSA,8mg/(kg·d))及N-乙酰-L-半胱氨酸(NAC,100mg/(kg·d));每周测定各组实验动物血糖值、摄食量和饮水量。给药4周后,测定血清中TC、TG、HDL-C、LDL-C含量;采用苏木素-伊红染色对肠系膜上动脉血管病理观察。结果:黑灵芝多糖具有显著降血糖、降血脂作用(P<0.05);黑灵芝多糖对Ⅱ型糖尿病大鼠多饮多食的症状具有显著的缓解作用;同时对糖尿病大鼠肠系膜上动脉病变具有保护作用,且其作用效果均优于CSA和NAC。结论:黑灵芝多糖可能通过调节糖尿病大鼠糖脂代谢途径改善糖尿病小动脉血管病变。

Objective： To explore the protective effect of polysaccharide from Ganoderma atrum on fasting blood glucose, serum lipids and superior mesenteric arteries of type Ⅱ diabetic rats. Methods： An animal model of type- Ⅱ diabetes was developed by feeding high fat diet/glucose to rats for a relative long period followed by an injection of low dose of STZ. The experimental rats were randomly divided into six groups： non-diabetic control group, high fat diet/glucose treated diabetic group, non-treated diabetic group, diabetic group treated with Ganoderma atrum polysaccharide （100 mg/（kg · d））, diabetic group treated with cyclosporine A （CSA, 8 mg/（kg · d）） and diabetic group treated with N-acetyl-L-cysteine （NAC, 100 mg/（kg · d））. Fasting blood glucose levels and food and water intake amounts were measured once a week. At the end of the 4-week experimental period, serum TC, TG and HDL-C levels and the histology of superior mesenteric arteries were assayed. Results： Ganoderma atrum polysaccharide exerted noticeable hypoglycemic and hypolipidemic effects （P 〈 0.05） in diabetic rats. Meanwhile, it could relieve symptoms including polydipsia, polyphagia and protect against the injury of superior mesenteric arteries. All the above beneficial effects were better than those of CSA and NAC. Conclusion： Ganoderma atrum polysaccharide may ameliorate arteriosclerotic narrowing of superior mesenteric arteries via regulating the glucose and lipid metabolism in type Ⅱ diabetic rats.